Tirzepatide is an approved medicine best known by a nickname: the "twincretin." The idea is simple even if the biology isn't — instead of copying one appetite-and-blood-sugar hormone like semaglutide does, tirzepatide copies two at once, with a single molecule.

In plain terms: semaglutide pulls one lever; tirzepatide pulls two.

The two-receptor mechanism

Your gut makes two "incretin" hormones after meals: GLP-1 and GIP. Both help manage blood sugar and appetite. Tirzepatide is a 39-amino-acid peptide engineered to switch on both receptors — GIP and GLP-1 — where semaglutide only hits GLP-12.

TirzepatideGIP receptorstronger engagementGLP-1 receptorweaker engagement
Fig. Tirzepatide is a single 39-residue peptide that activates two incretin receptors — GIP and GLP-1 — via one molecule (a dual agonist). Receptor-pharmacology analyses describe it as imbalanced, engaging the GIP receptor more than GLP-1. Semaglutide, by contrast, activates GLP-1 alone.

There's a subtlety worth knowing, because it's a real scientific finding most summaries skip: tirzepatide is "imbalanced." In lab studies it activates the GIP receptor more strongly than the GLP-1 receptor — it isn't an even 50/50 blend2. Exactly how much each pathway contributes to its effects is still being worked out.

Why once a week

Like semaglutide, tirzepatide carries a fatty-acid chain that binds albumin, stretching its half-life to about 5 days — long enough for weekly dosing, with levels building to a plateau over the first several weeks.

0w2w4w6w8wplateau
Fig. Weekly dosing accumulates: each tirzepatide dose lands before the previous has cleared, so levels build toward a plateau (steady-state) over roughly five half-lives. Single-dose decay (grey) versus repeated weekly dosing (gradient). An illustrative model from the published half-life, not a measurement.

See why GLP-1 medications are weekly and how long tirzepatide stays in your system.

What the trials actually found

Tirzepatide's trials produced some of the largest weight-loss figures seen for a medicine of this class:

TrialPeopleKey resultYear
SURMOUNT-11Adults with obesity, no diabetesAverage ~15% to 20.9% body-weight loss over 72 weeks, rising with dose2022
SURMOUNT-53751 adults, head-to-head vs semaglutideTirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks2025

In plain terms: on the highest dose in SURMOUNT-1, the average participant lost around a fifth of their body weight. And in 2025, the first head-to-head trial (SURMOUNT-5) found tirzepatide out-performed semaglutide for weight loss3. (Separate SURPASS diabetes trials showed strong blood-sugar control.)

Where it sits on the "ladder"

The incretin medicines keep adding targets: one receptor (semaglutide) → two (tirzepatide) → three (retatrutide, which adds a glucagon receptor). See retatrutide vs tirzepatide.

The brand names

Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (weight management) — same molecule, different approved uses (brand explainer).

Latest research (2024–2025)

  • SURMOUNT-5 (2025) was the milestone: the first head-to-head trial against semaglutide, and tirzepatide came out ahead on weight loss (20.2% vs 13.7%)3. Full context in semaglutide vs tirzepatide.
  • Trials have also extended tirzepatide beyond weight and diabetes — into areas like obstructive sleep apnea and heart failure with preserved ejection fraction — reflecting how quickly this drug class is expanding. We update this section as new results report.

The short version

Tirzepatide is an approved "twincretin" that activates two gut-hormone receptors — GIP more than GLP-1 — and produced up to ~21% average weight loss in SURMOUNT-1, beating semaglutide head-to-head in SURMOUNT-5. It lasts about five days, is dosed weekly, and sells as Mounjaro and Zepbound. Educational overview only, not medical advice.